O'Shaughnessy Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

O'Shaughnessy Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	–	–	2724
2021 Q3	$0	Sell	2 -120	-98%	-$400	﹤0.01%	2902
2021 Q2	$0	Hold	122	–	–	﹤0.01%	2734
2021 Q1	$0	Hold	122	–	–	﹤0.01%	2503
2020 Q4	$0	Hold	122	–	–	﹤0.01%	2277
2020 Q3	$0	Hold	122	–	–	﹤0.01%	2053
2020 Q2	$1K	Buy	+122	New	+$540	﹤0.01%	1688
2020 Q1	–	Sell	-2	Closed	–	–	1936
2019 Q4	$0	Buy	+2	New	+$8	﹤0.01%	1942

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

O'Shaughnessy Asset Management's PHAS Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 2 shares.

O'Shaughnessy Asset Management first reported a position in PHAS in Q4 2019 and held it in 7 quarters. The position peaked at $1K in Q2 2020. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 2 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021.
O'Shaughnessy Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
O'Shaughnessy Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q2 2020.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.